---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-288951"
form_type: "8-K"
ticker: null
cik: "0001780097"
company_name: "Baudax Bio, Inc."
filed_at: "2022-11-18T23:59:59+00:00"
generated_at: "2026-06-21T15:59:35.279947+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Baudax Bio receives Nasdaq delisting notice for negative stockholders' equity

## Summary
- Reported stockholders' equity of ($19,540,000) as of Sept 30, 2022, below Nasdaq's $2.5M minimum.
- Must submit compliance plan by December 30, 2022; if accepted, up to 180 days to regain compliance.
- Stock continues trading on Nasdaq Capital Market pending plan review and potential hearing.
- Company is evaluating options to resolve deficiency; no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001193125-22-288951
- form_type: 8-K
- cik: 0001780097
- company_name: Baudax Bio, Inc.
- filed_at: 2022-11-18T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1780097/000119312522288951/0001193125-22-288951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1780097/000119312522288951/d391567d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-288951
- JSON: https://secwatch.observer/filing/0001193125-22-288951.json
- Plain text: https://secwatch.observer/filing/0001193125-22-288951.txt

## Key facts
- Listing & Compliance Notices
  Baudax Bio, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: November 15, 2022, Baudax Bio, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. On its quarterly report for the quarter ended September 30, 2022, the Company reported stockholders’ equity of ($19,540,000), and, as a result, does not currently satisfy Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1780097/000119312522288951/0001193125-22-288951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.